Formycon AG (LON:0W4N)

Market Cap	354.28M -56.9%
Revenue (ttm)	41.96M -17.2%
Net Income	-144.17M
EPS	-8.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	888
Average Volume	1,043
Open	23.00
Previous Close	22.90
Day's Range	22.70 - 23.40
52-Week Range	19.10 - 54.80
Beta	0.58
RSI	41.27
Earnings Date	Mar 26, 2026

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 245
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0W4N

Financial Performance

Financial numbers in EUR